-
1
-
-
10744225097
-
Global burden of disease (GBD) for hepatitis C
-
The Global Burden of Hepatitis C Working Group
-
The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol. 2004;44:20-29.
-
(2004)
J. Clin. Pharmacol
, vol.44
, pp. 20-29
-
-
-
2
-
-
0033795196
-
Interferons: Cell signalling, immune modulation, antiviral response and virus countermeasures
-
Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 2000;81:2341-2364.
-
(2000)
J. Gen. Virol
, vol.81
, pp. 2341-2364
-
-
Goodbourn, S.1
Didcock, L.2
Randall, R.E.3
-
4
-
-
0032904403
-
Pharmacokinetic model for alpha interferon administered subcutaneously
-
Chatelut E, Rostaing L, Gregoire N, Payen JL, Pujol A, Izopet J, Houin G, Canal PA. Pharmacokinetic model for alpha interferon administered subcutaneously. Br. J. Clin. Pharmacol. 1999;47: 365-371.
-
(1999)
Br. J. Clin. Pharmacol
, vol.47
, pp. 365-371
-
-
Chatelut, E.1
Rostaing, L.2
Gregoire, N.3
Payen, J.L.4
Pujol, A.5
Izopet, J.6
Houin, G.7
Canal, P.A.8
-
5
-
-
0034324083
-
Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group
-
Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther. 2000;68:556-567.
-
(2000)
Clin. Pharmacol. Ther
, vol.68
, pp. 556-567
-
-
Glue, P.1
Fang, J.W.2
Rouzier-Panis, R.3
Raffanel, C.4
Sabo, R.5
Gupta, S.K.6
Salfi, M.7
Jacobs, S.8
-
7
-
-
18244377180
-
Structural and biologic characterization of pegylated recombinant IFN-α2b
-
Grace M, Youngster S, Gitlin G, Sydor W, Xie L, Westreich L, Jacobs S, Brassard D, Bausch J, Bordens R. Structural and biologic characterization of pegylated recombinant IFN-α2b. J. Interferon Cytokine Res. 2001;21:1103-1115.
-
(2001)
J. Interferon Cytokine Res
, vol.21
, pp. 1103-1115
-
-
Grace, M.1
Youngster, S.2
Gitlin, G.3
Sydor, W.4
Xie, L.5
Westreich, L.6
Jacobs, S.7
Brassard, D.8
Bausch, J.9
Bordens, R.10
-
8
-
-
0035086519
-
Rational design of a potent, long-lasting form of interferon: A 40-kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C
-
Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W, Graves M. Rational design of a potent, long-lasting form of interferon: a 40-kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug. Chem. 2001;12:195-202.
-
(2001)
Bioconjug. Chem
, vol.12
, pp. 195-202
-
-
Bailon, P.1
Palleroni, A.2
Schaffer, C.A.3
Spence, C.L.4
Fung, W.J.5
Porter, J.E.6
Ehrlich, G.K.7
Pan, W.8
Xu, Z.X.9
Modi, M.W.10
Farid, A.11
Berthold, W.12
Graves, M.13
-
9
-
-
0036750664
-
Pegylated interferons for the treatment of chronic hepatitis C infection
-
Luxon BA, Grace M, Brassard D, Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin. Ther. 2002;24:1363-1383.
-
(2002)
Clin. Ther
, vol.24
, pp. 1363-1383
-
-
Luxon, B.A.1
Grace, M.2
Brassard, D.3
Bordens, R.4
-
10
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
-
(2001)
Lancet
, vol.358
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
Rustgi, V.K.4
Shiffman, M.5
Reindollar, R.6
Goodman, Z.D.7
Koury, K.8
Ling, M.9
Albrecht, J.K.10
-
11
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002;347:975-982.
-
(2002)
N. Engl. J. Med
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
Smith, C.4
Marinos, G.5
Goncales Jr, F.L.6
Haussinger, D.7
Diago, M.8
Carosi, G.9
Dhumeaux, D.10
Craxi, A.11
Lin, A.12
Hoffman, J.13
Yu, J.14
-
12
-
-
13844303527
-
Pegylated interferon alfa-2a (40kDa) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients
-
Shobokshi OA, Serebour FE, Skakni L, Al-Jaser N, Tantawe AO, Sabah A, Dinish T, Al-Quaiz M, Qatani K, Sandokji A, Al-Blowi A, Karawi M, Al-Kayyal B, Al-Momen S, Akbar H, Ayoola A, El-Hazmi M, El-Hazmi I, Humaida A, Eissa H, Khawajah F, Al-Khalifa M. Pegylated interferon alfa-2a (40kDa) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients. Saudi Med. J. 2003;24(Suppl 2):S92.
-
(2003)
Saudi Med. J
, vol.24
, Issue.SUPPL. 2
-
-
Shobokshi, O.A.1
Serebour, F.E.2
Skakni, L.3
Al-Jaser, N.4
Tantawe, A.O.5
Sabah, A.6
Dinish, T.7
Al-Quaiz, M.8
Qatani, K.9
Sandokji, A.10
Al-Blowi, A.11
Karawi, M.12
Al-Kayyal, B.13
Al-Momen, S.14
Akbar, H.15
Ayoola, A.16
El-Hazmi, M.17
El-Hazmi, I.18
Humaida, A.19
Eissa, H.20
Khawajah, F.21
Al-Khalifa, M.22
more..
-
13
-
-
0037338922
-
Predicting antiviral treatment response in chronic hepatitis C: How accurate and how soon?
-
Lee SS, Abdo AA. Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon? J. Antimicrob. Chemother. 2003;51:487-491.
-
(2003)
J. Antimicrob. Chemother
, vol.51
, pp. 487-491
-
-
Lee, S.S.1
Abdo, A.A.2
-
14
-
-
0033045004
-
Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein
-
Bowen S, Tare N, Inoue T, Yamasaki M, Okabe M, Horii I, Eliason JF. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp. Hematol. 1999;27:425-432.
-
(1999)
Exp. Hematol
, vol.27
, pp. 425-432
-
-
Bowen, S.1
Tare, N.2
Inoue, T.3
Yamasaki, M.4
Okabe, M.5
Horii, I.6
Eliason, J.F.7
-
15
-
-
0036498813
-
Biological assays for interferons
-
Meager A. Biological assays for interferons. J. Immunol. Methods 2002;261:21-36.
-
(2002)
J. Immunol. Methods
, vol.261
, pp. 21-36
-
-
Meager, A.1
-
16
-
-
4344559759
-
Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C
-
Boulestin A, Kamar N, Legrand-Abravanel F, Sandres-Saune K, Alric L, Vinel JP, Rostaing L, Izopet J. Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C. Antimicrob. Agents Chemother. 2004;48:3610-3612.
-
(2004)
Antimicrob. Agents Chemother
, vol.48
, pp. 3610-3612
-
-
Boulestin, A.1
Kamar, N.2
Legrand-Abravanel, F.3
Sandres-Saune, K.4
Alric, L.5
Vinel, J.P.6
Rostaing, L.7
Izopet, J.8
-
17
-
-
0035858379
-
Improvements in protein pegylation: Pegylated interferons for treatment of hepatitis C
-
Kozlowski A, Harris JM. Improvements in protein pegylation: pegylated interferons for treatment of hepatitis C. J. Control. Release 2001;72:217-224.
-
(2001)
J. Control. Release
, vol.72
, pp. 217-224
-
-
Kozlowski, A.1
Harris, J.M.2
-
18
-
-
0022596342
-
Functionally important conserved amino acids in interferon-alpha 2 identified with analogues produced from synthetic genes
-
Gamble R, Petter NN, Trueman P, Newton CR, Carr FJ, Hockney RC, Moore VE, Greene AR, Holland D, Edge MD. Functionally important conserved amino acids in interferon-alpha 2 identified with analogues produced from synthetic genes. Biochem. Biophys. Res. Commun. 1986;134:1404-1411.
-
(1986)
Biochem. Biophys. Res. Commun
, vol.134
, pp. 1404-1411
-
-
Gamble, R.1
Petter, N.N.2
Trueman, P.3
Newton, C.R.4
Carr, F.J.5
Hockney, R.C.6
Moore, V.E.7
Greene, A.R.8
Holland, D.9
Edge, M.D.10
-
19
-
-
0027227660
-
Structural, functional and evolutionary implications of the three-dimensional crystal structure of murine interferon-beta
-
Mitsui Y, Senda T, Shimazu T, Matsuda S, Utsumi J. Structural, functional and evolutionary implications of the three-dimensional crystal structure of murine interferon-beta. Pharmacol. Ther. 1993;58:93-132.
-
(1993)
Pharmacol. Ther
, vol.58
, pp. 93-132
-
-
Mitsui, Y.1
Senda, T.2
Shimazu, T.3
Matsuda, S.4
Utsumi, J.5
-
20
-
-
0036208536
-
Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin
-
Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, Esteban R. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002;35:930-936.
-
(2002)
Hepatology
, vol.35
, pp. 930-936
-
-
Buti, M.1
Sanchez-Avila, F.2
Lurie, Y.3
Stalgis, C.4
Valdes, A.5
Martell, M.6
Esteban, R.7
-
21
-
-
0344643418
-
Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection
-
Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, Gangl A, Kessler H, Ferenci P. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. J. Viral Hepat. 2003;10:37-42.
-
(2003)
J. Viral Hepat
, vol.10
, pp. 37-42
-
-
Jessner, W.1
Stauber, R.2
Hackl, F.3
Datz, C.4
Watkins-Riedel, T.5
Hofer, H.6
Gangl, A.7
Kessler, H.8
Ferenci, P.9
-
22
-
-
4344625164
-
Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: A randomized, controlled study
-
Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, Filice G. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antivir. Ther. 2004;9:491-497.
-
(2004)
Antivir. Ther
, vol.9
, pp. 491-497
-
-
Bruno, R.1
Sacchi, P.2
Ciappina, V.3
Zochetti, C.4
Patruno, S.5
Maiocchi, L.6
Filice, G.7
|